Investigating a protein's role in eye diseases that cause vision loss
Official title: Ref-1 in Retinal Neovascularization
Funded at Indiana University Indianapolis · NIH-11117193 · Data updated 2026-11-12
This study is looking for new ways to help people with vision problems caused by conditions like retinopathy of prematurity and diabetic retinopathy, by testing a protein that could lead to better oral medications for treating these eye issues.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Indiana University Indianapolis NIH-funded |
| Lab location | 1 site (Indianapolis, United States) |
| Project start | June 14, 2023 |
| Project end | June 13, 2026 |
| Funding year | 2025 |
| Award (this year) | $33,538 |
| NIH project number | 5F31EY035171-03 |
| Project ID | NIH-11117193 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals suffering from retinal neovascularization due to conditions like diabetic retinopathy or retinopathy of prematurity.
✕Less likely to help
Patients with retinal diseases not related to neovascularization may not benefit from this research.
What this research studies
This research focuses on retinal neovascularization, a condition that leads to vision impairment in diseases like retinopathy of prematurity and diabetic retinopathy. The study aims to develop new therapies that target multiple pathways involved in these diseases, rather than relying solely on current treatments that often have high burdens and resistance issues. By exploring the role of a protein called APE1/Ref-1, which is linked to the regulation of factors involved in neovascularization, the research seeks to find more effective treatment options. Patients may benefit from potential new oral medications that could reduce the severity of their eye conditions.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for preventing vision loss in patients with retinal diseases.
How similar studies have gone: Previous studies have shown promise in targeting similar pathways for treating retinal diseases, indicating potential for success in this approach.
Where this research is happening
-
Indiana University Indianapolis
Indianapolis, United States Active
Researchers
- Principal investigator: Hartman, Gabriella — Indiana University Indianapolis
- Study coordinator: Hartman, Gabriella
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.